← All Cybin INC filings

Cybin INC F-1 registration statements

The S-1’s counterpart for foreign private issuers registering shares for sale in the United States.

CYBN
Cybin INC
F-10: Cybin Ups Shelf Prospectus to $1.7B, Shifts to Nasdaq
Cybin Inc. increased its multi-jurisdictional shelf prospectus to $1.7 billion and announced a U.S. stock exchange transfer to Nasdaq Global Market, effective January 5, 2026.
CYBN
Cybin INC
F-10/A: Cybin Files $800M Shelf Prospectus, Updates Clinical Programs
Cybin Inc. filed an amended shelf prospectus to raise up to $800 million, detailing progress in its psychedelic therapeutic programs and a recent CEO transition.
CYBN
Cybin INC
F-10: Cybin Files $1 Billion Shelf Prospectus to Fund Psychedelic Drug Development
Cybin Inc. has filed a preliminary base shelf prospectus to offer up to $1 billion in various securities, aiming to secure future funding for its clinical-stage psychedelic therapeutics pipeline targeting mental health conditions.
CYBN
Cybin INC
F-10: Cybin Inc. Files F-10 Registration Statement, Increases Shelf Offering to $650 Million
Cybin Inc. has filed an F-10 registration statement with the SEC, increasing its shelf offering from $400 million to $650 million, to support its ongoing clinical programs.
CYBN
Cybin INC
F-10POS: Cybin Inc. Amends Shelf Prospectus to Include Securities Sales by Existing Securityholders
Cybin Inc. has filed a post-effective amendment to its short form base shelf prospectus to allow for the potential sale of securities by existing securityholders.